Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
    • Topics A-Z
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
    • Topics A-Z
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Genetics
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues

Share

August 2019; 5 (4) ArticleOpen Access

Human GABRG2 generalized epilepsy

Increased somatosensory and striatothalamic connectivity

Mangor Pedersen, Magdalena Kowalczyk, Amir Omidvarnia, Piero Perucca, Samuel Gooley, Steven Petrou, Ingrid E. Scheffer, Samuel F. Berkovic, Graeme D. Jackson
First published June 7, 2019, DOI: https://doi.org/10.1212/NXG.0000000000000340
Mangor Pedersen
From the The Florey Institute of Neuroscience and Mental Health (M.P., M.K., A.O., S.P., I.E.S., G.D.J.), Parkville; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville; Department of Neuroscience (P.P.), Central Clinical School, Monash University; Department of Neurology (P.P.), The Royal Melbourne Hospital, Parkville; Department of Neurology (P.P.), Alfred Health, Melbourne; Department of Medicine (P.P., S.P.), The Royal Melbourne Hospital, The University of Melbourne, Parkville; Epilepsy Research Centre (S.G., I.E.S., S.F.B., G.D.J.), Department of Medicine, The University of Melbourne, Austin Health, Heidelberg; and Department of Pediatrics (I.E.S.), The University of Melbourne, Parkville, VIC, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Magdalena Kowalczyk
From the The Florey Institute of Neuroscience and Mental Health (M.P., M.K., A.O., S.P., I.E.S., G.D.J.), Parkville; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville; Department of Neuroscience (P.P.), Central Clinical School, Monash University; Department of Neurology (P.P.), The Royal Melbourne Hospital, Parkville; Department of Neurology (P.P.), Alfred Health, Melbourne; Department of Medicine (P.P., S.P.), The Royal Melbourne Hospital, The University of Melbourne, Parkville; Epilepsy Research Centre (S.G., I.E.S., S.F.B., G.D.J.), Department of Medicine, The University of Melbourne, Austin Health, Heidelberg; and Department of Pediatrics (I.E.S.), The University of Melbourne, Parkville, VIC, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amir Omidvarnia
From the The Florey Institute of Neuroscience and Mental Health (M.P., M.K., A.O., S.P., I.E.S., G.D.J.), Parkville; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville; Department of Neuroscience (P.P.), Central Clinical School, Monash University; Department of Neurology (P.P.), The Royal Melbourne Hospital, Parkville; Department of Neurology (P.P.), Alfred Health, Melbourne; Department of Medicine (P.P., S.P.), The Royal Melbourne Hospital, The University of Melbourne, Parkville; Epilepsy Research Centre (S.G., I.E.S., S.F.B., G.D.J.), Department of Medicine, The University of Melbourne, Austin Health, Heidelberg; and Department of Pediatrics (I.E.S.), The University of Melbourne, Parkville, VIC, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Piero Perucca
From the The Florey Institute of Neuroscience and Mental Health (M.P., M.K., A.O., S.P., I.E.S., G.D.J.), Parkville; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville; Department of Neuroscience (P.P.), Central Clinical School, Monash University; Department of Neurology (P.P.), The Royal Melbourne Hospital, Parkville; Department of Neurology (P.P.), Alfred Health, Melbourne; Department of Medicine (P.P., S.P.), The Royal Melbourne Hospital, The University of Melbourne, Parkville; Epilepsy Research Centre (S.G., I.E.S., S.F.B., G.D.J.), Department of Medicine, The University of Melbourne, Austin Health, Heidelberg; and Department of Pediatrics (I.E.S.), The University of Melbourne, Parkville, VIC, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel Gooley
From the The Florey Institute of Neuroscience and Mental Health (M.P., M.K., A.O., S.P., I.E.S., G.D.J.), Parkville; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville; Department of Neuroscience (P.P.), Central Clinical School, Monash University; Department of Neurology (P.P.), The Royal Melbourne Hospital, Parkville; Department of Neurology (P.P.), Alfred Health, Melbourne; Department of Medicine (P.P., S.P.), The Royal Melbourne Hospital, The University of Melbourne, Parkville; Epilepsy Research Centre (S.G., I.E.S., S.F.B., G.D.J.), Department of Medicine, The University of Melbourne, Austin Health, Heidelberg; and Department of Pediatrics (I.E.S.), The University of Melbourne, Parkville, VIC, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Petrou
From the The Florey Institute of Neuroscience and Mental Health (M.P., M.K., A.O., S.P., I.E.S., G.D.J.), Parkville; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville; Department of Neuroscience (P.P.), Central Clinical School, Monash University; Department of Neurology (P.P.), The Royal Melbourne Hospital, Parkville; Department of Neurology (P.P.), Alfred Health, Melbourne; Department of Medicine (P.P., S.P.), The Royal Melbourne Hospital, The University of Melbourne, Parkville; Epilepsy Research Centre (S.G., I.E.S., S.F.B., G.D.J.), Department of Medicine, The University of Melbourne, Austin Health, Heidelberg; and Department of Pediatrics (I.E.S.), The University of Melbourne, Parkville, VIC, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ingrid E. Scheffer
From the The Florey Institute of Neuroscience and Mental Health (M.P., M.K., A.O., S.P., I.E.S., G.D.J.), Parkville; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville; Department of Neuroscience (P.P.), Central Clinical School, Monash University; Department of Neurology (P.P.), The Royal Melbourne Hospital, Parkville; Department of Neurology (P.P.), Alfred Health, Melbourne; Department of Medicine (P.P., S.P.), The Royal Melbourne Hospital, The University of Melbourne, Parkville; Epilepsy Research Centre (S.G., I.E.S., S.F.B., G.D.J.), Department of Medicine, The University of Melbourne, Austin Health, Heidelberg; and Department of Pediatrics (I.E.S.), The University of Melbourne, Parkville, VIC, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samuel F. Berkovic
From the The Florey Institute of Neuroscience and Mental Health (M.P., M.K., A.O., S.P., I.E.S., G.D.J.), Parkville; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville; Department of Neuroscience (P.P.), Central Clinical School, Monash University; Department of Neurology (P.P.), The Royal Melbourne Hospital, Parkville; Department of Neurology (P.P.), Alfred Health, Melbourne; Department of Medicine (P.P., S.P.), The Royal Melbourne Hospital, The University of Melbourne, Parkville; Epilepsy Research Centre (S.G., I.E.S., S.F.B., G.D.J.), Department of Medicine, The University of Melbourne, Austin Health, Heidelberg; and Department of Pediatrics (I.E.S.), The University of Melbourne, Parkville, VIC, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Graeme D. Jackson
From the The Florey Institute of Neuroscience and Mental Health (M.P., M.K., A.O., S.P., I.E.S., G.D.J.), Parkville; Department of Neurology (I.E.S.), Royal Children's Hospital, Parkville; Department of Neuroscience (P.P.), Central Clinical School, Monash University; Department of Neurology (P.P.), The Royal Melbourne Hospital, Parkville; Department of Neurology (P.P.), Alfred Health, Melbourne; Department of Medicine (P.P., S.P.), The Royal Melbourne Hospital, The University of Melbourne, Parkville; Epilepsy Research Centre (S.G., I.E.S., S.F.B., G.D.J.), Department of Medicine, The University of Melbourne, Austin Health, Heidelberg; and Department of Pediatrics (I.E.S.), The University of Melbourne, Parkville, VIC, Australia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Human GABRG2 generalized epilepsy
Increased somatosensory and striatothalamic connectivity
Mangor Pedersen, Magdalena Kowalczyk, Amir Omidvarnia, Piero Perucca, Samuel Gooley, Steven Petrou, Ingrid E. Scheffer, Samuel F. Berkovic, Graeme D. Jackson
Neurol Genet Aug 2019, 5 (4) e340; DOI: 10.1212/NXG.0000000000000340

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
695

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective To map functional MRI (fMRI) connectivity within and between the somatosensory cortex, putamen, and ventral thalamus in individuals from a family with a GABAergic deficit segregating with febrile seizures and genetic generalized epilepsy.

Methods We studied 5 adults from a family with early-onset absence epilepsy and/or febrile seizures and a GABAA receptor subunit gamma2 pathogenic variant (GABRG2[R43Q]) vs 5 age-matched controls. We infer differences between participants with the GABRG2 pathogenic variant and controls in resting-state fMRI connectivity within and between the somatosensory cortex, putamen, and ventral thalamus.

Results We observed increased fMRI connectivity within the somatosensory cortex and between the putamen and ventral thalamus in all individuals with the GABRG2 pathogenic variant compared with controls. Post hoc analysis showed less pronounced changes in fMRI connectivity within and between the primary visual cortex and precuneus.

Conclusions Although our sample size was small, this preliminary study suggests that individuals with a GABRG2 pathogenic variant, raising risk of febrile seizures and generalized epilepsy, display underlying increased functional connectivity both within the somatosensory cortex and in striatothalamic networks. This human network model aligns with rodent research and should be further validated in larger cohorts, including other individuals with generalized epilepsy with and without known GABA pathogenic variants.

Glossary

CI=
confidence interval;
fMRI=
functional MRI

We previously reported an Australian family with a GABA type A receptor subunit gamma2 pathogenic variant (GABRG2[R43Q]) presenting with febrile seizures, febrile seizures plus, and absence epilepsy.1 This family has decreased cortical inhibition, demonstrated by transcranial magnetic stimulation,2 and decreased cortical benzodiazepine receptor binding on PET.3 Aligning with human data, mice with the same Gabrg2[R43Q] pathogenic variant have reduced cortical inhibition shown by deficits in GABA-mediated synaptic currents in the somatosensory cortex and anatomic changes in cortical interneuron positioning.4,5

Although these investigations provide clues about the mechanisms underlying the GABRG2 pathogenic variant, it is unknown whether brain connectivity is affected in humans with the R43Q pathogenic variant. To study this issue, we quantified changes in functional MRI (fMRI) connectivity in individuals with this GABRG2 pathogenic variant. We focused on regions previously studied in Gabrg2 mice: the somatosensory cortex, the ventral thalamus, and the putamen (as a recent fMRI study in rats demonstrated that GABAA antagonists enhance connectivity of the somatosensory cortex and striatum6). Together, these 3 brain regions comprise a well-known pathway where the cortex sends excitatory signals to the putamen, which in turn exerts strong inhibitory control over the ventral thalamus via the globus pallidus and substantia nigra pars reticulata before relaying excitatory information back to the cortex.

Based on previous research in humans with the GABRG2[R43Q] pathogenic variant2,3 and mice with the Gabrg2[R43Q] pathogenic variant,4,5,7 we hypothesize that fMRI connectivity within the somatosensory cortex and between subcortical regions is altered in people with a GABRG2 pathogenic variant.

Methods

Participants and clinical information

We recruited 5 adults from a previously reported family with the GABRG2 [R43Q] pathogenic variant1 (mean age [SD]: 36.4 ± 4.2 years; clinical information in the table). They were compared with 5 age- and sex-matched controls (mean age [SD] 36.8 ± 4.1 years).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table

Clinical, EEG and imaging phenotype of individuals with the R43Q GABRG2 pathogenic variant1

Standard protocol, approvals, and patient consents

This study was approved by the Austin Human Research Ethics Committee, and participants gave written informed consent to participate.

fMRI preprocessing

We acquired 10 minutes of resting-state fMRI data on a Siemens 3T Skyra scanner with a voxel size of 3 × 3 × 3 mm and repetition time of 3 seconds. The fMRI data were slice-timing corrected, realigned, coregistered to T1 images, tissue segmented, spatially normalized, and filtered between 0.01 and 0.08 Hz. See reference 8 for further details about our fMRI methods.

fMRI connectivity analysis

We used 2 different estimates of fMRI connectivity. (1) Regional homogeneity: to calculate voxel-averaged local connectivity within each node of our brain network model (somatosensory cortex, ventral thalamus, and putamen). This measures Kendall W correlations between a single voxel and its 26 nearby voxels in three-dimensional space. Its values range between 0 (minimal local connectivity) and 1 (maximal local connectivity). (2) Partial correlation: to calculate voxel-averaged Pearson correlations of fMRI time series between each node pair, while regressing out indirect correlation effects from all other connection pairs. Partial correlation values range between −1 (maximal negative correlation) and 1 (maximal positive correlation).

Effect size analysis

We used Hedges' g standardized effect sizes and 95th percentile confidence intervals (95% CIs) to quantify mean differences in brain connectivity between individuals with the GABRG2 pathogenic variant and controls (as Hedges' g is recommended over Cohen's d in studies with a limited sample sizes). Hedges' g effect sizes = 0.2 (small); 0.5 (moderate); 0.8 (large); and 1.2 (very large).

Data availability

Anonymized original data will be shared by request from any qualified investigator.

Results

GABRG2: fMRI connectivity is increased within the somatosensory cortex

We observed stronger fMRI connectivity within the somatosensory cortex in all individuals with the GABRG2 pathogenic variant compared with controls (Hedges' g = 1.46; 95% CI = 0.43–2.41—figure, A). Hedges' g effect sizes were lower between GABRG2 and healthy controls for fMRI connectivity within the putamen (Hedges' g = 0.55; CI 95 = −0.85–1.84) and ventral thalamus (Hedges' g = 0.40; CI 95 = −0.96 to 1.70).

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Functional connectivity within and between brain nodes in GABRG2 participants displayed by purple magenta color bars and healthy controls displayed by blue cyan color bars

Peak regional homogeneity across all voxels within the somatosensory cortex (A), putamen (B), and ventral thalamus (C), and partial correlations averaged across all voxels between the somatosensory cortex-putamen (D), somatosensory cortex-ventral thalamus (E), and ventral thalamus-putamen (F). Error bars denote the standard error across participants. There was little difference in head movement between groups (mean movement [SD] in GABRG2 = 0.12 mm ± 0.05; mean movement [SD] in controls = 0.16 mm ± 0.04). Our 3 brain regions of interest—(1) bilateral somatosensory cortex (yellow); (2) putamen (orange); and (3) ventral thalamus (red) (G)—were delineated using the NeuroSynth database (neurosynth.org) incorporating findings from a multitude of previous fMRI studies describing these brain regions and their behavioral correlates, as well as their functional connectivity patterns. *A and F had large effect size.

GABRG2: fMRI connectivity is increased between the thalamus and putamen

We observed stronger fMRI connectivity between the putamen and ventral thalamus in all individuals with the GABRG2 pathogenic variant compared with controls (Hedges' g = 1.98; 95% CI = 0.11–3.45—figure, F). It is worth noting that the GABRG2 participant with strongest connectivity also experienced seizures into adulthood (see participant 2 in the table for more clinical information). There were no large effect sizes between GABRG2 and controls for fMRI connectivity between the putamen and somatosensory cortex (Hedges' g = 0.68; 95% CI = −0.75–1.98) or the ventral thalamus and somatosensory cortex (Hedges' g = 0.26; 95% CI = −1.09 to 1.55).

GABRG2: post hoc analysis shows less fMRI connectivity changes of the visual cortex and precuneus

To test whether our primary result was specific to the somatosensory cortex, thalamus, and putamen or it reflected a “whole-brain process”, we analyzed 2 additional brain nodes: (1) primary visual cortex and (2) precuneus. We observed no large effect size in fMRI connectivity for these 2 brain regions between GABRG2 and control participants. fMRI connectivity within the visual cortex: Hedges' g = 0.45; 95% CI = −0.93 to 1.74. fMRI connectivity within the precuneus: Hedges' g = 0.25; 95% CI = −1.12 to 1.56. fMRI connectivity between the visual cortex and precuneus: Hedges' g = 0.43; 95% CI = −0.95–1.72.

Discussion

We found that 5 individuals with a GABRG2 pathogenic variant and a history of seizures (5/5 febrile seizures; 3/5 absence seizures) have increased fMRI connectivity within the somatosensory cortex and between the putamen and ventral thalamus compared with 5 healthy controls. This finding suggests a “network-specific” rather than a “whole-brain” effect, as our post hoc analysis revealed no difference in connectivity between GABRG2 and control participants of either the primary visual cortex or the precuneus.

Emerging animal research has highlighted the important role of specific brain areas in generalized epilepsy, in particular absence epilepsy where seizures are thought to originate in the somatosensory cortex9 and are modulated by thalamostriatal circuits.10 Although it is not straightforward to compare animal and human studies, our findings provide preliminary evidence that somatosensory cortex and subcortical structures are hyperconnected in people with a genetic predisposition to develop febrile and also absence seizures. This finding is further supported by our previous GABRG2 transcranial magnetic stimulation study—in the same family—showing neuronal hyperexcitability of the perimotor cortex.2

It is nontrivial to quantify whether microscale neuronal dysfunction and macroscale fMRI connectivity are related because of their vast difference in spatial scales. However, this study presented us with an opportunity to (indirectly) assess whether inhibitory neuronal dysfunction is reflected in fMRI connectivity, as we know that people with a GABRG2 pathogenic variant have abnormal inhibitory GABAergic neuronal function. We postulate that our fMRI connectivity findings are related to inhibitory neuronal abnormalities, especially hyperconnectivity between the thalamus and the putamen, as the latter brain region consists almost exclusively of medium spiny inhibitory GABAergic neurons.

Our small sample size is a consequence of the difficulty of recruiting a single family with a genetically homogenous disorder to the demands of an imaging study that requires travel and attendance at a single site. Despite this limitation, our preliminary findings give insight into network changes that may underlie human genetic epilepsy caused by a GABRG2 pathogenic variant, and they align with results from the Gabrg2 animal model, which also shows increased activity of the somatosensory cortex.4 Nevertheless, our human network model based on this family with a GABRG2 variant should be further validated in larger generalized epilepsy cohorts with and without known GABA pathogenic variants.

Study funding

The Florey Institute of Neuroscience and Mental Health acknowledges the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant. They also acknowledge the facilities and the scientific and technical assistance of the National Imaging Facility (NIF) at the Florey node and The Victorian Biomedical Imaging Capability (VBIC). This study was supported by the National Health and Medical Research Council (NHMRC) of Australia, grant numbers 628952 and 1060312 (GJ Practitioner Fellowship) and program grant number 1091593 (S. Petrou, I. E. Scheffer, S. F. Berkovic, and G. D. Jackson).

Disclosure

Disclosures available: Neurology.org/NG.

Acknowledgment

The authors thank Susannah Bellows for recruiting the participants with the GABRG2 pathogenic variant.

Appendix Authors

Table
Table

Footnotes

  • Go to Neurology.org/NG for full disclosures. Funding information is provided at the end of the article.

  • The Article Processing Charge was funded by the authors.

  • Received January 28, 2019.
  • Accepted in final form April 29, 2019.
  • Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Marini C,
    2. Harkin LA,
    3. Wallace RH,
    4. Mulley JC,
    5. Scheffer IE,
    6. Berkovic SF
    . Childhood absence epilepsy and febrile seizures: a family with a GABAA receptor mutation. Brain 2003;126:230–240.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Fedi M,
    2. Berkovic SF,
    3. Macdonell RAL,
    4. Curatolo JM,
    5. Marini C,
    6. Reutens DC
    . Intracortical hyperexcitability in humans with a GABAA receptor mutation. Cereb Cortex 2008;18:664–669.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Fedi M,
    2. Berkovic SF,
    3. Marini C,
    4. Mulligan R,
    5. Tochon-Danguy H,
    6. Reutens DC
    . A GABAA receptor mutation causing generalized epilepsy reduces benzodiazepine receptor binding. Neuroimage 2006;32:995–1000.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Tan HO,
    2. Reid CA,
    3. Single FN, et al
    . Reduced cortical inhibition in a mouse model of familial childhood absence epilepsy. Proc Natl Acad Sci U S A 2007;104:17536–17541.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Wimmer VC,
    2. Li MYS,
    3. Berkovic SF,
    4. Petrou S
    . Cortical microarchitecture changes in genetic epilepsy. Neurology 2015;84:1308–1316.
    OpenUrl
  6. 6.↵
    1. Nasrallah FA,
    2. Singh KKDR,
    3. Yeow LY,
    4. Chuang KH
    . GABAergic effect on resting-state functional connectivity: dynamics under pharmacological antagonism. Neuroimage 2017;149:53–62.
    OpenUrl
  7. 7.↵
    1. Currie SP,
    2. Luz LL,
    3. Booker SA,
    4. Wyllie DJA,
    5. Kind PC,
    6. Daw MI
    . Reduced local input to fast-spiking interneurons in the somatosensory cortex in the GABAA γ2 R43Q mouse model of absence epilepsy. Epilepsia 2017;58:597–607.
    OpenUrl
  8. 8.↵
    1. Pedersen M,
    2. Curwood EK,
    3. Vaughan DN,
    4. Omidvarnia AH,
    5. Jackson GD
    . Abnormal brain areas common to the focal epilepsies: multivariate pattern analysis of fMRI. Brain Connect 2016;6:208–215.
    OpenUrl
  9. 9.↵
    1. Meeren HK,
    2. Pijn JP,
    3. Van Luijtelaar EL,
    4. Coenen AM,
    5. Lopes da Silva FH
    . Cortical focus drives widespread corticothalamic networks during spontaneous absence seizures in rats. J Neurosci 2002;22:1480–1495.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Slaght SJ,
    2. Paz T,
    3. Chavez M,
    4. Deniau JM,
    5. Mahon S,
    6. Charpier S
    . On the activity of the corticostriatal networks during spike-and-wave discharges in a genetic model of absence epilepsy. J Neurosci 2004;24:6816–6825.
    OpenUrlAbstract/FREE Full Text

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Study funding
    • Disclosure
    • Acknowledgment
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post Hoc Analysis of the EXTEND-IA TNK Trials

Dr. Nicole Sur and Dr. Mausaminben Hathidara

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All Epilepsy/Seizures
  • All Genetics
  • fMRI
  • Functional neuroimaging
  • Absence seizures

Alert Me

  • Alert me when eletters are published

Recommended articles

  • What's Happening
    What's happening in Neurology® Genetics
    et al.
    Neurology, August 12, 2019
  • Article
    Imaging of neuroinflammation in migraine with aura
    A [11C]PBR28 PET/MRI study

    Daniel S. Albrecht, Caterina Mainero, Eri Ichijo et al.
    Neurology, March 27, 2019
  • Articles
    Sensorimotor overactivity as a pathophysiologic trait of embouchure dystonia
    B. Haslinger, E. Altenmüller, F. Castrop et al.
    Neurology, May 31, 2010
  • Article
    Change in brain network connectivity during PACAP38-induced migraine attacks
    A resting-state functional MRI study
    Faisal Mohammad Amin, Anders Hougaard, Stefano Magon et al.
    Neurology, December 16, 2015
Neurology Genetics: 9 (3)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Genetics | Online ISSN: 2376-7839

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise